Search

The article reports on entrepreneurs Nat Turner and Zach Weinberg, founders of medical data firm Flatiron Health. It mentions the collection of data on cancer treatments from electronic medical records, the big data analysis to provide hospitals more real-time information on treatments, and the various funding opportunities for the company.

The article presents twenty sets of 30 revolutionary thinkers under the age of 30. It includes the actress Liza Koshy, diagnostics company Mammoth Biosciences founder Trevor Martin, Perksy mobile app developer Nadia Masri, PlayVS app for esports developer Delane Parnell, and women's clothing company Staud funder Sarah Staudinger.

The article discusses various aspects of the Tarrytown, New York-based Regeneron Pharmaceuticals Inc. (Regeneron) firm which is led by cofounder Leonard Schleifer, and it mentions Schleifer's criticism of the pricing practices at other drug companies. The costs associated with Regeneron's Eylea eye drug and Dupixent eczema medication are examined, along with scientist George Yancopoulos who is also one of Regeneron's cofounders. Business revenue and stock share prices are assessed.

The article profiles several U.S. women entrepreneurs. Those profiled include former technology executive Meg Whitman, chairwoman Diane Hendricks of the roofing firm ABC Supply, and owner Marian Ilitch of the pizza chain Little Caesars Pizza. Also noted are founder Judy Faulkner of the software firm Epic, cofounder Johnelle Hunt of the trucking firm J.B. Hunt Transport Services, and television host Oprah Winfrey.

The article reports on the new biotechnology company Unity Biotechnology and its founder Nathaniel David. It reports on the company's aim to find a drug to prevent aging, David's work at founding and funding previous biotech firm Kythera Biopharmaceuticals Inc, and his work with Unity chief executive Keith Leonard.

The article presents 100 business attributes and ideas from contemporary business people, entertainers, and designers. It mentions such attributes as social advocacy, discussed by musician Bono, mentoring, discussed by Chinese real estate magnate Lee Shau Kee and music producer Russell Simmons, and reputation, discussed by businessman Vinod Khosla and designer Miuccia Prada.

The article discusses the American pharmaceutical company Vertex Pharmaceuticals' development of an expensive drug to treat patients with cystic fibrosis (CF). An overview of the Vertex chief executive Jeffrey (Jeff) Leiden's role in changing Vertex's model of drug development, including in focusing on research and development (R&D) investment, is provided.

The article offers a list of innovative companies throughout the world, including the application software company Salesforce.com, the automobile manufacturer Tesla and the direct marketing retail company Amazon.com.

The article discusses Craig Venter and his introduction of the thorough Health Nucleus physical exam which costs each participant $25,000 and includes blood tests, MRIs, an ultrasound, a cognitive test, and a CT scan. Topics include funding for Venter's firm, Human Longevity from investors including Celgene and GE Ventures, Venter's efforts to use DNA information to improve human longevity, and Venter's success as sequencing his own complete DNA in the late 1990's.

The article discusses big data in relation to executive Owen Tripp and his Grand Rounds Inc. medical referral firm which matches patients with physicians, and it mentions how Grand Rounds Inc. raised 100 million dollars in capital and has a valuation of close to one billion dollars as of 2016. According to the article, the company uses health insurance-claims data, biographical information, and a database of nearly 700,000 doctors to grade physicians based on the quality of their work.

The article discusses the life of billionaire pharmaceutical entrepreneur John Kapoor, and it mentions his roles as the founder, chairman, and chief executive officer of the U.S.-based INSYS Therapeutics Inc. drug company, as well as the claim that Kapoor let his pharmaceutical firms push legal and ethical limits while developing and selling medications such as blood-pressure pills. Kapoor's childhood in India is examined, along with cancer pain management and sales of the drug Sybsys.

The article examines pharmaceutical company GlaxoSmithKline (GSK) under the leadership of Chief Executive Officer (CEO) Andrew Witty. It discusses poor revenue and share prices under Witty before focusing on his efforts to repair the public image of the company following illegal marketing and bribery accusations.

The article focuses on pharmaceutical company BioMarin which focuses on drug therapy of ultrarare disorders. It talks about cost control measures from chief executive officer Jean-Jacques Bienaimé to increase corporate profitability. It comments when BioMarin has a market capitalization of nearly 15 billion dollars and is expected to turn its first profit from continued operations in 2017. It mentions BioMarin licensed a gene therapy treatment for hemophilia.

The article offers a profile of venture capitalist Robert Nelsen. The author reflects on Nelsen's investments in the biotechnology industry through his Arch Venture Partners company. Emphasis is given to topics such as the seed funding for the company Illumina which enabled affordable personal DNA sequencing, Nelsen's early focus on biology, and his interest in aging with companies such as Unity Biotechnology.

The article discusses a rapid decline in the value of the pharmaceutical company, Valeant Pharmaceuticals, amid accusations of mismanagement and mischievous financial activity. Topics include scrutiny of Valeant for its drug-pricing policies and an undisclosed mail-order pharmacy called Philidor Rx, chief executive officer J. Michael Pearson's departure from Valeant, and pressure on Pearson from Valeant's executive compensation plan to maintain growth and stock prices for long periods of time.

The article discusses the world's boldest business leaders as of May 2016, according to the publication. Topics include Marc Benioff, the founder and chief executive officer (CEO) of the cloud-computing company Salesforce.com, Jeff Bezos, the founder and CEO of the electronic-commerce company Amazon.com, and Rahul Bhatia, the co-founder of the low-cost airline IndiGo.

The article discusses Turkish-American engineering Ph.D. Osman Kibar and his biotechnology startup, Samumed. Topics include significant investments made in Samumed due to its creation of medicines that allegedly reverse aging by causing cells of aging people to rapidly regenerate, Kibar's founding of the biotechnology startup Genoptix and co-founding of the antenna manufacturer E-Tenna, and research on Wnt genes by Samumed's chief scientific officer and co-founder, John Hood.

The article examines problems surrounding pricing in the pharmaceutical industry. Particular focus is given to executive Martin Shkreli, whose company Turing Pharmaceuticals purchased the drug Daraprim and raised its price significantly in pursuit of profit. According to the author, Shkreli's actions and attitudes are illustrative of similar problems within the industry as a whole. Details on Shkreli's career as a hedge fund manager and his company Retrophin are presented. The firm Valeant Pharmaceutical is also discussed.

The article discusses the role of the pharmaceutical firm Axovant Sciences and its founder, Vivek Ramaswamy, in buying drugs that are neglected by large pharmaceutical firms. Topics include Ramaswamy's use of the holding firm Roivant Sciences, his career as a hedge fund analyst for the firm QVT Financial in light of his biotechnology expertise, and Roivant's purchase of the Alzheimer's drug RVT-101 from the firm GlaxoSmithKline. The spin-off and initial public offering (IPO) of Axovant is noted.

The article examines how a biotech innovation involving the use of proteins made by a particular gene to treat cancer has led to more companies competing over drug prices and higher stock prices. It looks at why companies are interested despite the low number of patients that qualify for such treatment due to faster approval from the Food and Drug Administration.

The article reports on the development of the drug Jakafi by pharmaceutical company Incyte Corp. for the treatment of myelofibrosis. It mentions the work of executive Paul Friedman and his successor Herve Hoppenot in expanding the work of Incyte, the use of future drugs in combination therapy, and the company's focus on making drug molecules in-house.

The article looks at the development of drugs to treat neurological and psychiatric disorders including Alzheimer's disease and depression. It says the volume of drug research activity in the neuroscience area fell for several years beginning in the 1990s but is now rising again, citing factors including promising developments in genetics research. It offers a list of drug companies working in this area that it says offer positive investment opportunities.

The article looks at the pharmaceutical industry, focusing on trends in the structure of the industry and on the activities of Brenton "Brent" Saunders, chief executive of drug company Actavis. It reports on various mergers and acquisitions Saunders has overseen, including Actavis's acquisition of drug company Allergan, and says he has made significant profits for shareholders without developing any new drugs.

The article discusses the work of Dr. Patrick Soon-Shiong, who is attempting to bring high technology and big data to medicine. Topics include the scope of the project, which promises to lessen poor treatment recommendations, speed care, and lower costs; a discussion of Soon-Shiong's reputation and accomplishments in medicine and business; and a discussion of how feasible the project is.

The article presents information on Illumina, a company that manufactures integrated systems for the analysis of genetic variation and biological function. Topics include the role of DNA-sequencing machines in diagnosing and treating diseases such as Cancer, details on Illumina's Chief Executive Office (CEO) Jay Flatley, and statistics on the sales and profit of Illumina.

The article discusses the pharmaceutical firm Biogen Idec Inc. and its chief executive officer George Scangos as of December 2012, focusing on an analysis of Scangos' work in streamlining the company's corporate vision and the development of core programs aimed at driving up the value of the pharmaceutical company. Scangos' work as a scientist is mentioned, along with fellow pharmaceutical firm Genentech's financial success following the release of its cancer drug Avastin. Biogen Idec Inc.'s drug Avonex, which is used to combat several relapsing forms of multiple sclerosis, is also examined.

The article looks at the philanthropic efforts of Paul Allen, co-founder of the computer software company Microsoft, focusing on his establishment of a neuroscience research institute, the Allen Institute for Brain Science in Seattle, Washington. It describes some of the work being done at the institute, including the development of innovative brain imaging technologies. It cites his mother's Alzheimer's disease and ensuing dementia as a key motivation in his decision to found the institute. Its large-scale project of assembling an atlas of the human brain is described.

The article profiles biotechnology companies like Alexion Pharmaceuticals and Genzyme, which develop drugs to treat niche diseases like Gaucher disease and rare causes of anemia. Although traditionally the pharmaceutical industry does not favor entrepreneurs or small businesses, these companies focus on treating rare diseases or symptoms in order to market their products. Topics include the success of former Yale Medical School professor Leonard Bell's drug Soliris, approved to treat anemia and rare kidney disease atypical hemolytic uremic syndrome, how the U.S. Affordable Care Act made niche drugs available to mass markets, a history of Alexion from its founding, and how Genzyme pioneered the ultrarare drugs market. INSET: AGE OF THE ULTRA-ORPHANS.

The article discusses Neal Patterson and Cerner, a medical information-technology company he co-founded in 1979. Cerner specializes in software to analyze the digitized medical records it stores, and could benefit enormously from a 2009 U.S. law that strongly encourages hospitals to digitize. Cerner estimates its revenues could quadruple to $10 billion within eight years. Details are presented about Patterson's history with the company, and the concerns of those who question the value of digitized medical records. INSET: ObamaCare will not be overturned by the Supreme Court.

The article discusses the Gardasil vaccine produced by pharmaceutical firm Merck & Co., and the public perception regarding the product. It states that Gardasil is designed to fight the cervical cancer-causing human papilloma virus (HPV), but the public's view towards sexually transmitted diseases has limited its usage among patients. The reputation of Merck & Co. has reportedly been tainted by its aggressive promotion of Vioxx, an anti-arthritis pill which allegedly caused heart attacks. The drug approval process of the U.S. Food & Drug Administration (FDA) is also examined. Several charts are presented regarding Gardasil, including a graph which details the growing threat of throat cancer. INSET: THE SCRIPT: A CANCER CONTROVERSY.

The article focuses on Novartis pharmaceutical research company and its chief executive officer (CEO) Joseph Jimenez Jr. who was selected by CEO Daniel Vasella to succeed him. Novartis' 2011 annual sales for Diovan hypertension and Gleevec chronic myelogenous leukemia drugs are noted, as well as projections for 2020 sales. Novartis' stock price has exceeded other drugmakers on the S&P 500 and Amex Pharmaceutical indexes since 2002. Jimenez comments on the company's diversification strategy and business model.

The article discusses the efforts of American business magnate and philanthropist Bill Gates and his organization, the Bill and Melinda Gates Foundation, to spread the availability of vaccines and help eradicate disease. It comments on how his work to save lives relates to the demographic ideas of economist and scholar Thomas Malthus. Gates' work to eradicate polio and malaria and his efforts to help form the Global Alliance for Vaccines & Immunisation, known as the GAVI Alliance, are also considered. INSETS: THE SCRIPT: GATES REINVENTS GIVING;SMALL VICTORIES, BIG BATTLES AHEAD.

The article presents a chart of where in the U.S. job growth has occurred in 2011, professions that pay over an annual income of one hundred thousand dollars, and the best cities in the U.S. for job growth. A graph shows the amount of growth in the U.S. service sector and the number of self-employed people between 2006 and 2011. Statistics are offered on the U.S. companies that have increased their employees the most in one year including the information technology company Cognizant Technology Solutions, computer manufacturer Apple Inc., and electronic commerce company Amazon.com.

The article looks at Bernard Munos, a former executive at pharmaceutical company Eli Lilly, and the innovations he recommends to improve the pharmaceutical and drug industry. Munos has published two scientific papers in which he discussed the need to make the resources of drug companies available to scientists outside the industry and examined the amount of money being spent to develop new drugs. Pharmaceutical companies including Pfizer, Sanofi-Aventis, and Zafgen have followed his advice by cutting research and development budgets and establishing networks with outside researchers. INSETS: Munos' Laws;Six Pharma Rebels.

The article focuses on the possible breakup of pharmaceutical manufacturer Pfizer. It states that Pfizer chief executive officer Ian Read suggested in February 2011 that the company was considering spinning out adjacent businesses to create increased value for shareholders. It comments that Pfizer has merged with other pharmaceutical companies over the years, including Warner-Lambert in 2000, Pharmacia in 2003, and Wyeth in 2009. It mentions that Pfizer has spent 70 billion dollars in research and development from 2001 to 2011 but only seen two drugs that passed 1 billion dollars in annual sales and that while it had nine new medications approved by the U.S. Food and Drug Administration between 2000 and 2010, most were not profitable. INSETS: Patent Protectors;Sharpening Their Scalpels.

The article discusses entrepreneur Jonathan Rothberg and a gene-decoding machine developed by his startup company, Ion Torrent. Rothberg's Personal Genome Machine (PGM) is 24 inches wide and costs $50,000, making it both the smallest and least-expensive gene decoder available. Within two hours it can read several million letters of genetic code. The device could find application in a number of fields including nanotechnology, agriculture, and medicine. By the year 2012 Rothberg says he will have a machine ready that will need just two hours to decode all human genes that code for proteins. INSET: In Brief: Soul of a New Machine.

This article discusses the efficacy of foods that are sold as drugs. The article cites the example of Probugs, a yogurtlike drink for kids that is supposed to be good for the child's digestive system and is supposed to alleviate diarrhea associated with antibiotics. Tests have shown that the food doesn't do what it claims. Foods with supplements that are supposed to improve the consumer's health are becoming a popular trend.

The article discusses the agricultural biotechnology company Monsanto. Monsanto has accumulated billions of dollars in revenue creating genetically engineered seeds which help make crops immune to herbicides and ward off potentially damaging insects. According to the author, despite Monsanto's economic success it has been the subject of public criticism for its efforts to genetically modify crops including corn and soybeans. INSET: THE SOYBEAN SOLUTION.

The article discusses heart disease. Topics include statistics on heart disease, progress that has been made in combating it, aspects of the disease that remain puzzling to researchers, recommendations for prevention and methods of treatment, and the mysterious nature and incidence of sudden cardiac arrest. INSETS: Sudden Cardiac Death;Heart Attack;Angina;Heart Failure

The article is about patient advocacy groups that help speed up the process of testing experimental drugs. Numerous groups exist, including the Cystic Fibrosis Foundation, the Leukemia & Lymphoma Society, and the Multiple Myeloma Research Foundation. These groups raise money for drug research and provide patients for clinical trials. These efforts help drug companies develop drugs faster and more efficiently.

The article focuses on Fred Hassan, Chief Executive Officer of the pharmaceutical company Schering-Plough. Hassan is regarded as one of the industry's most talented executives, but is facing a crisis caused by the company's anticholestermic agent Zetia. Schering-Plough delayed the release of clinical trials showing Zetia had limited affect on preventing heart attacks for 18 months. The resulting controversy threatens Zetia's profitability, and the company's stock price has fallen. INSET: The Reviver.

The article reports on the medical advances that allow humans genetic screening for cancer. Patients will be able to learn whether or not they carry the cancer gene, and then make decisions according to their personal beliefs and needs. The genetic testing allowed one woman to verify the existence of her breast and ovarian cancer genes, which resulted in her decision to have both breasts and ovaries removed. INSETS: THE TELLTALE TUMOR;NEVER MIND YOU--WHAT ABOUT ME?.

The article focuses on Cincinnati Children's Hospital and how organizational and management-style changes helped cut down on errors, improve efficiency, save patient lives, and improve profits. Little things like reducing work space and distance in the pharmacy cut the turnaround time for nonurgent bedside medications and reduced the number of medications thrown out. Adding a 30 second pre-op pause before surgery helped make sure all safety steps were taken. Poor job performers were let go.

This article describes the controversy over some high-tech medical devices. Johnson & Johnson and Boston Scientific's drug-coated stent is one of these. The tiny, stainless-steel mesh tube has been implanted in over four million people. Each year a quarter of a million heart-failure patients are implanted with Implantable Cardioverter Defibrillators, devices made by Medtronic, Boston Scientific and St. Jude Medical. But, increasingly, their safety is being called into question. INSET: The Bionic Man.

The article reports in the increase in the number of people suffering from diabetes in 2006. The steep rise is attributed to the number of individuals leading sedentary lives, consuming poor diets and the general aging of the U.S.population. The build up in numbers has proven a boon to the pharmaceutical industry which expects the sale of diabetes drugs to rise between 2006 and 2011, more than doubling from $12 billion to $26 billion.

The article reports on biotechnologist Drew Endy's attempts to develop a way to edit the individual DNA units of living organisms. Through synthetic biology, Endy predicts that we will be able to program DNA to be reproducing machines, creating cells that can keep track of their age and bacteria programed to kill tumor cells. Endy is one of four founders of Condon Devices, which hopes to industrialize the construction of genes.

This article reports that, while anti-abortionists view embryonic stem cell research as akin to murder, many U.S. billionaires see it as a great way to save lives. Sidestepping U.S. President George W. Bush's ban on federal funding of most stem-cell experiments, Eli Broad, the founder of KB Home Corp., donated $25 million to erect a stem-cell building. Anti-ban donors include New York Mayor Michael Bloomberg, Dolby sound system inventor Ray Dolby, Oracle founder Larry Ellison, and the Michael J. Fox Foundation.

The article discusses the unseen epidemic of drug-resistant infections in the United States. The author discusses how drug-resistant infections kill more Americans than AIDS and breast cancer combined. He discusses what hospitals are doing to fight infections. He also discusses how small boutique pharmaceutical companies are conducting research on a whole new variety of drugs. INSETS: Clean Hands;War Wounds.